Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Potential of Physical Withdrawal From Intravenous CR845 (Difelikefalin) in Hemodialysis Patients
Conditions
Interventions
CR845 0.5 mcg/kg
Placebo
Locations
5
United States
Cara Therapeutics Study Site
Bridgeport, Connecticut, United States
Cara Therapeutics Study Site
Hartford, Connecticut, United States
Cara Therapeutics Study Site
Kansas City, Kansas, United States
Cara Therapeutics Study Site
Roseville, Michigan, United States
Cara Therapeutics Study Site
Minneapolis, Minnesota, United States
Start Date
December 31, 2019
Primary Completion Date
June 11, 2020
Completion Date
June 11, 2020
Last Updated
September 8, 2022
NCT07462741
NCT07179705
NCT07033260
NCT06960304
NCT06438445
NCT05612022
Lead Sponsor
Cara Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions